Endometriosis: current and future medical therapies
Vercellini, P.; Somigliana, E.; Viganò, P.; Abbiati, A.; Daguati, R.; Crosignani, P.G.
Best Practice and Research. Clinical Obstetrics and Gynaecology 22(2): 275-306
2008
ISSN/ISBN: 1521-6934 PMID: 18036995 DOI: 10.1016/j.bpobgyn.2007.10.001Document Number: 199312
Endometriosis is a chronic inflammatory disease that responds to steroidal manipulation. Creation of a steady hormonal environment with inhibition of ovulation temporarily suppresses the ectopic implants and reduces the inflammatory status as well as the associated pain symptoms. Pharmacological management of endometriosis must be set within the framework of long-term therapeutic strategies. As the available drugs are not curative, treatments will need to be administered for years or until women desire a pregnancy. The various therapies studied have shown similar efficacy. Consequently, based on a more favourable profile in terms of safety, tolerability and cost, combined oral contraceptives and progestins should be considered as the first-line option, both as an alternative to surgery and as a postoperative adjuvant measure. Gonadotrophin-releasing hormone analogues, danazol and gestrinone should be used when progestins and oral contraceptives fail, are not tolerated or are contra-indicated. Future therapies for endometriosis must compare favourably with existing drugs before hypothesizing their implementation in current practice. Medical treatment is not indicated in women seeking conception because reproductive prognosis is not ameliorated.
Document emailed within 0-6 h
